Autoantibodies News and Research

RSS

FDA approves first-ever type 1 diabetes delaying drug Tzield (teplizumab-mzwv)

On November 17, 2022, the US Food and Drug Administration (FDA) approved a pathbreaking new drug called Tzield. This injectable formulation contains a combination of two drugs that could push back the onset of type 1 diabetes (T1D) in adults at stage 3 and children aged eight years or more at stage 2.

20 Nov 2022

Study highlights the need for early and timely diagnosis of type 1 diabetes in children and adolescents

If children and young people have already developed metabolic imbalances (diabetic ketoacidosis) at the time of diagnosis of type 1 diabetes (T1D), this can result in complications such as extended stays in hospital, poorer long-term control of blood sugar levels, brain edema, or even a higher mortality rate.

8 Nov 2022

Rare variants of type I IFN immunity genes could underlie life-threatening COVID-19

Researchers assessed whether loss-of-function variants of type I interferon immunity genes are associated with life-threatening COVID-19.

27 Oct 2022

Research suggests that ORF6 is a major SARS-CoV-2 innate immune antagonist

In a recent study posted to the bioRxiv* server, researchers in the United States demonstrated how severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) open reading frame 6 (ORF6) protein contributes to viral pathogenesis and modulates the host's immune responses.

23 Oct 2022

Study provides unique picture of blood sugar dynamics and autoimmunity in early childhood

When and why does type 1 diabetes manifest in children? For the first time, researchers conducted a long-term study on infants and young children with increased genetic risk of type 1 diabetes.

19 Oct 2022

What is the impact of COVID-19 and organophosphates on cardiac health?

In a new study, researchers discussed the impacts of organophosphates (OP) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections on cardiovascular (CVS) health.

17 Oct 2022

Immune-mediated inflammatory diseases following COVID-19

Researchers explore the potential association between SARS-CoV-2 infection and immune-mediated inflammatory diseases.

12 Oct 2022

Treatment for neurological diseases often no longer effective enough in the later stages

Neurological diseases often begin with an inflammatory process and the degradation of the so-called myelin layer, which surrounds the nerve fibers (axons) like a protective insulating layer.

28 Sep 2022

Most people infected with SARS-CoV2 recover within 12 months, study finds

A McMaster University-led study has found that most people infected with the SARS-CoV2 virus recover within 12 months, irrespective of the severity.

22 Sep 2022

Brain injury a common consequence of both COVID-19 and influenza

In a recent study published in the journal Brain, researchers reported that brain injury is common in coronavirus disease 2019 (COVID-19) and influenza.

12 Sep 2022

Review explores the involvement of the endothelium as an important underpinning of long COVID’s pathophysiology

Researchers discussed possible mechanisms and potential treatment methods for endotheliopathy observed in patients with post-acute sequelae of SARS-CoV-2 infection.

6 Sep 2022

The origins, breadth, and resolution of autoreactivity in severe COVID-19

Researchers assessed naïve B cells and autoreactivity in severe COVID-19.

2 Sep 2022

What are the unique traits of Long COVID?

In a new study, researchers identified distinctive characteristics of post-acute sequelae of COVID-19 (PASC) via immune profiling.

12 Aug 2022

Persistent viral infections within hosts cause post-acute sequelae of COVID-19, research shows

A research team, comprised of Associate Professor Tomonari Sumi of the Research Institute for Interdisciplinary Science at Okayama University and Associate Professor Kouji Harada of the Center for IT-based Education at Toyohashi University of Technology, has developed a mathematical model of the immune response within infected hosts that considers systemic infection of a novel coronavirus (SARS-CoV-2), and demonstrated by conducting experimental computer simulations that persistent viral infections within hosts potentially cause long COVID or post-acute sequelae of COVID-19.

3 Aug 2022

Autoantibodies News and Research

FDA approves first-ever type 1 diabetes delaying drug Tzield (teplizumab-mzwv)

Study highlights the need for early and timely diagnosis of type 1 diabetes in children and adolescents

Rare variants of type I IFN immunity genes could underlie life-threatening COVID-19

Research suggests that ORF6 is a major SARS-CoV-2 innate immune antagonist

Study provides unique picture of blood sugar dynamics and autoimmunity in early childhood

What is the impact of COVID-19 and organophosphates on cardiac health?

Immune-mediated inflammatory diseases following COVID-19

Treatment for neurological diseases often no longer effective enough in the later stages

Most people infected with SARS-CoV2 recover within 12 months, study finds

Brain injury a common consequence of both COVID-19 and influenza

Review explores the involvement of the endothelium as an important underpinning of long COVID’s pathophysiology

The origins, breadth, and resolution of autoreactivity in severe COVID-19

What are the unique traits of Long COVID?

Persistent viral infections within hosts cause post-acute sequelae of COVID-19, research shows

Plasma myosin light chain 9 levels may be better predictor of COVID-19 severity than blood biomarkers

What is the immunopathogenesis of pediatric COVID-19?

How COVID-19 affects the brain microvasculature

What is the long-term protection against COVID-19?

Persistence of SARS-CoV-2 in tissues leads to long COVID

UT Southwestern researchers reveal the physical mechanism behind a neurological autoimmune disease

Antibodies eBook

Exploring the intersection of biology and proteomics

Unlocking the Secrets of Multiple Sclerosis Progression: Brain-Immune Cell Communication

Passing on Polycystic Ovary Syndrome: Health risks for male offspring of women with PCOS

Latest News